Latest Insider Transactions at Adaptive Biotechnologies Corp (ADPT)
This section provides a real-time view of insider transactions for Adaptive Biotechnologies Corp (ADPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adaptive Biotechnologies Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adaptive Biotechnologies Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
6,771
-95.86%
|
$385,947
$57.87 P/Share
|
|
Mar 01
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
6,771
+34.03%
|
$40,626
$6.79 P/Share
|
|
Mar 01
2021
|
Michael J Pellini Director |
SELL
Open market or private sale
|
Direct |
20,000
-100.0%
|
$1,140,000
$57.8 P/Share
|
|
Mar 01
2021
|
Michael J Pellini Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$120,000
$6.55 P/Share
|
|
Mar 01
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-74.35%
|
$870,000
$58.39 P/Share
|
|
Mar 01
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 26
2021
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
2,812
-30.02%
|
$154,660
$55.44 P/Share
|
|
Feb 26
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,812
+30.44%
|
$19,684
$7.18 P/Share
|
|
Feb 26
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-100.0%
|
$840,000
$56.23 P/Share
|
|
Feb 26
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 25
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
14,675
-97.96%
|
$821,800
$56.73 P/Share
|
|
Feb 25
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
14,675
+50.0%
|
$88,050
$6.55 P/Share
|
|
Feb 24
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-54.37%
|
$855,000
$57.91 P/Share
|
|
Feb 24
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 23
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-54.04%
|
$825,000
$55.25 P/Share
|
|
Feb 23
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 22
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-70.76%
|
$900,000
$60.67 P/Share
|
|
Feb 22
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 19
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
416
-100.0%
|
$25,376
$61.2 P/Share
|
|
Feb 19
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
416
+50.0%
|
$2,496
$6.27 P/Share
|
|
Feb 19
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-63.45%
|
$930,000
$62.27 P/Share
|
|
Feb 19
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 18
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-69.64%
|
$900,000
$60.85 P/Share
|
|
Feb 18
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 17
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-67.34%
|
$915,000
$61.96 P/Share
|
|
Feb 17
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 16
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
SELL
Open market or private sale
|
Direct |
16,250
-48.68%
|
$1,040,000
$64.43 P/Share
|
|
Feb 16
2021
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Exercise of conversion of derivative security
|
Direct |
16,250
+50.0%
|
$503,750
$31.71 P/Share
|
|
Feb 16
2021
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
16,250
-44.05%
|
$1,040,000
$64.43 P/Share
|
|
Feb 16
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
16,250
+48.08%
|
$503,750
$31.71 P/Share
|
|
Feb 16
2021
|
Francis Lo Chief People Officer |
SELL
Open market or private sale
|
Direct |
2,000
-100.0%
|
$130,000
$65.45 P/Share
|
|
Feb 16
2021
|
Francis Lo Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$14,000
$7.8 P/Share
|
|
Feb 16
2021
|
Robert Hershberg Director |
SELL
Open market or private sale
|
Direct |
2,000
-57.08%
|
$130,000
$65.45 P/Share
|
|
Feb 16
2021
|
Robert Hershberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+36.34%
|
$0
$0.45 P/Share
|
|
Feb 16
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-55.66%
|
$975,000
$65.04 P/Share
|
|
Feb 16
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 16
2021
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
6,000
-79.96%
|
$390,000
$65.08 P/Share
|
|
Feb 16
2021
|
Michelle Renee Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+44.43%
|
$42,000
$7.8 P/Share
|
|
Feb 15
2021
|
David E. Goel Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,504
+50.0%
|
-
|
|
Feb 14
2021
|
Michael J Pellini Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,504
+50.0%
|
-
|
|
Feb 14
2021
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,504
+50.0%
|
-
|
|
Feb 14
2021
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,504
+50.0%
|
-
|
|
Feb 14
2021
|
Peter M Neupert Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,504
+50.0%
|
-
|
|
Feb 14
2021
|
Eric Dobmeier Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,504
+50.0%
|
-
|
|
Feb 14
2021
|
Michelle Renee Griffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,504
+50.0%
|
-
|
|
Feb 12
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-58.49%
|
$975,000
$65.87 P/Share
|
|
Feb 12
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 11
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-85.76%
|
$945,000
$63.39 P/Share
|
|
Feb 11
2021
|
Julie Rubinstein President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.55 P/Share
|
|
Feb 10
2021
|
Julie Rubinstein President |
SELL
Open market or private sale
|
Direct |
15,000
-69.37%
|
$945,000
$63.5 P/Share
|